Benefits of CELLEX™
Benefits of CELLEX™
The new THERAKOS™ CELLEX™ Photopheresis System features several improvements designed to enhance the patient treatment experience. These include an automated closed system design that provides operators with the ability to switch between double and single needle treatment, and a new separation technology designed to separate white cells from whole blood. These improvements result in shorter treatment times and the ability to treat a greater range of patients. The benefits of reduced risk of infection and cross-contamination are maintained in CELLEX™ Photopheresis System.
Shorter treatment times
Patients can be treated more rapidly with the THERAKOS™ CELLEX™ Photopheresis System because THERAKOS™ CELLEX™ Photopheresis System is able to operate in double-needle mode, which enables continuous blood collection and return from and to the patient. Treatment times are also reduced because the constant spinning of the centrifuge allows clean separation, resulting in highly efficient leukocyte collection. These advances mean that time per treatment can be reduced from 3 hours to approximately 1 hour, so that patients will be able to spend less time receiving treatment.
The benefits of shorter treatment time may include improved patient comfort, which may in turn increase patients’ ability to comply with treatment. Shorter treatment times may also make therapy more acceptable for people who receive extra corporeal photopheresis (ECP) as outpatients, as they will need to spend less time in hospital.
The shorter ECP treatment times achieved with THERAKOS™ CELLEX™ may also enable centres to increase productivity and increase service efficiency. This can result in decreased departmental costs as the cost per treatment may be reduced as more treatments are carried out. Shorter, more predictable treatment times can create the potential for more efficient scheduling and better resource management. Ultimately, more patients may benefit from ECP.
The new THERAKOS™ CELLEX™ Photopheresis System allows for the treatment of a broader range of patients through technological advancements that improve the management and efficiency of extracorporeal and residual blood volume exchange, and provide the flexibility to tailor the ECP procedure to individual patient needs.
As the THERAKOS™ CELLEX™ Photopheresis System operates safely and effectively using a significantly lower extracorporeal and residual blood volume, this makes it possible to treat patients with a lower body weight, including paediatric patients, and haemodynamically unstable patients. The lower residual blood volume (at the end of treatment) also enables anaemic patients and patients with cardiac or pulmonary insufficiency to safely receive photopheresis.
Improved photopheresis process
The THERAKOS™ CELLEX™ Photopheresis System provides state-of-the-art technology in a single, complete and integrated closed system device. The technology encompassed in the new CELLEX™ Photopheresis System means that clinicians can provide patients with an improved ECP process, and enables clinicians to customise treatment parameters based on the patient’s current status.
With integrated technologies for cell collection, photoactivation, and reinfusion, the new CELLEX™ technology provides:
- A better view of fluid volume
- The capacity for red blood cells (RBCs) and plasma to be returned simultaneously with photoactivation
- An improved cell separation and collection fraction
- Higher white blood cell (WBC) yield
- Consistent and appropriate cellular ultraviolet-A (UVA) exposure
- Automated photoactivation
- A highly interactive and informative customer interface
With the THERAKOS™ CELLEX™ Photopheresis System, the user has the ability to control fluid management by using the dual-needle mode, while being able to effortlessly change to single-needle mode if one access point fails during treatment. The THERAKOS™ CELLEX™ state-of-the-art Photopheresis System also allows ECP to be delivered by a single operator, which provides a new level of control for the photopheresis process.